Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.

Amir T Fathi Haesook T Kim Robert J Soiffer Mark J Levis Shuli Li Annette S Kim Zachariah DeFilipp Areej R El-Jawahri Steve L McAfee Andrew M Brunner Philip C Amrein Alice S Mims Laura W Knight Devon Kelley Aj S Bottoms Lindsey H Perry Jonathan L Wahl Jennifer Brock Elayne Breton Dylan M Marchione Vincent T Ho Yi-Bin Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Ivosidenib is safe and well-tolerated as maintenance therapy following HCT. Cumulative incidence of relapse and NRM, as well as estimations of PFS and OS, were promising in this phase 1 study.

Keyphrases

acute myeloid leukemia
stem cell transplantation
open label
clinical trial
bone marrow
study protocol
phase iii
wild type
phase ii
randomized controlled trial
allogeneic hematopoietic stem cell transplantation
low grade
stem cells
free survival
combination therapy
high dose
double blind
hematopoietic stem cell